We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
SHINGRIX (GlaxoSmithKline Australia Pty Ltd)
Product name
SHINGRIX
Date registered
Evaluation commenced
Decision date
Approval time
207 working days (255)
Active ingredients
recombinant Varicella Zoster Virus glycoprotein E antigen
Registration type
NCE/NBE
Indication
SHINGRIX (powder for suspension and suspension for injection) is indicated for the prevention of herpes zoster and post-herpetic neuralgia in adults 50 years of age or older.